Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This was an open-label, multicenter study in children ≤ 12 years of age with cystic fibrosis
(CF) and chronic Pseudomonas aeruginosa (PA) infection in the lower airways using three
28-day courses of Aztreonam for Inhalation Solution (AZLI) 75 mg three times daily, each
followed by 28 days off AZLI. The total treatment duration was to be 6 months.